We present a fast and simple direct enzyme immunoassay for the sexual steroid hormone estradiol-17/3 in serum of women enrolled in an in vitro fertilization and embryo transfer program. We added 25 L of standards or samples and 125 t. of a mixture of monoclonal antibody and displacing agents to the wells of a microtiter plate previously coated with a second antibody. After 30 mm 50 pL estradiol-horseradish peroxidase conjugate is added. Total incubation time is 75 mm. The immunoassay is stopped by washing the microtiter plate. The amount of bound conjugate is then measured at 450 nm with hydrogen peroxide as a substrate and 3,3',5,5'-tetramethylbenzidine as chromogen. tively low molecular weight, and its low cost (4). In addition, HRP can easily be bound to antigens, e.g., to steroid hormones
in immunoassay has, however, some disadvantages. They can be an eventual health hazard and disposal of the resulting wastes is difficult. In addition, the label ('I) is unstable and the measuring instrumentation is expensive.
Enzymes could be an attractive alternative. Since the first introduction of enzymes as markers in imxnunoassay (1, 2), many enzyme immunoassays (ELAs) have been developed. About 50% of the new enzyme-labeled EIAs use horseradish peroxidase (HRP) as a marker enzyme (3). The popularity of HRP is at least partly due to its high turnover number, its rela- tively low molecular weight, and its low cost (4). In addition, HRP can easily be bound to antigens, e.g., to steroid hormones (5) (6) (7) (8) . Until now, several EIAs for E2 have been described (8-14), most of which use HRP as the labeling enzyme. These assays, however, require long incubation times and most of them are not direct: they require extraction of E2 with organic solvents, which is laborious and error-prone. This extraction can, however, be omitted by using agents that displace E2 from its binding proteins 
Serum Specimens
Blood was sampled from stimulated women who enrolled in an WF-ET program. The patients were stimulated either with clomiphene and human menopausal gonadotropins (hMG) or with a gonadotropin-releasing hormone (GnBH) agonist (nasal spray of buserelin, Suprefact, or depot injection of goserelin, Zoladex) and hMG. Sera were analyzed directly or stored at -20 #{176}C until analysis. Although repeated freezing and thawing of the sera did not affect the measured E2 concentration, sera used for internal quality control (e.g., in the assessment of between-assay variation)
were divided into portions and stored frozen.
We analyzed 303 serum samples with our routine RIA kit (Fertigenix E2 RIA-CT, Medgenix Diagnostics, Fleui-us, Belgium). Nineteen samples with an E2 concentration <0.46 nmol/L, i.e., the lowest EIA standard, were not used. Consequently 284 samples were included for analytical evaluation of the present EIA method. Their
E2 concentrations
determined by RIA were 0A6-1.5 (98 sera), 1.5-3 (54 sera), 3-6 (82 sera), 6-10 (39 sera), and >10 nmol E2/L (11 sera).
Procedures
Preparation of the nionoclonal antibody. The monoclonal antibody 2F9 was prepared as described previously (22) . A 1/100 substock of this antibody was prepared in assay buffer and stored at 4#{176}C. 
Results

Choice of DisplacingAgents
In the absence of displacing agents, E2 remains mainly bound to its binding proteins in serum. As a result of this, only part of the steroid can bind to the antibody in the immunoassay.
For this reason mean E2 concentrations in the absence of displacing agents are 21.3% (SD 14.2%) lower than in the presence of displacing agents (n =24 sera with E2 concentrations varying between 0.81 and 14.65 nmol/L). To make possible direct and accurate measurement of E2 in serum, the addition of displacing agents is thus mandatory.
In some instances 100 g 8-anilino-1-naphthalenesulfonic acid (ANSA) has been used as a good displacing agent, e.g., in a direct EIA for E2 (8) . In several direct immunoassays for progesterone, danazol was used for this purpose (23-25) . In the present assay neither danazol nor ANSA yielded satisfactory results. The use of these displacing agents resulted in a good calibration curve, but accurate analysis of samples was not possible because of high variation coefficients (intra-assay CVs: from 10.7% to 239%; interassay CVs: from 12.4% to 42.3%). Better results were obtained with a combination of 10.5 ng each of danazol and 5a-dthydrotestosterone plus 0.28 ng mesterolone as displacing agents (intraassay CVs: from 5.6% to 13.2%; interassay CVs: from 8.5% to 25.6%). The best results were obtained with a combination containing 10 ng of each danazol, cortisol, and mesterolone per well (intraassay CVs: from L3% to 7.2%; interassay CVs: from 4.5% to 15.4%) (see also Table 1 ).
Analytical Variables
Calibration curve. Figure 1 shows the dose-response curve obtained with the direct EIA for E2. The detection limit, calculated as the least amount of E2 significantly different from zero at 95% confidence limits, was determined from 10 replicate measurements of the assay response at zero dose. It was 0.24 nmol/L or 1.6 pg/well.
Specificity. Cross-reactivities of the monoclonal antibody 2F9 as determined with the present method and with two other methods (15,22) are presented in Table 2 .
Analytical recovery. We added four to five different amounts of E2, ranging from 0.74 to 11.76 nmol/L, to each Sample dilution. When displacing agents were used, we diluted 2-to 16-fold nine samples containing between 5.28 and 14.7 nmol E2/L, with assay buffer, containing 45 g HSAIL. As Figure 2A shows, we found a linear correlation between the expected (x) and observed (y) values: y = L02x -0.04 nmol/L (Spearman correlation coefficient r = 0.980, n = 31).
The same nine samples were also assayed without displacing agents. Their mean concentration is 24.7% lower than in the presence of displacing agents. However, in the sample dilution experiment (2-to 16-fold dilutions with assay buffer, containing per liter 45 g HSA) a linear correlation was found between the expected (x) and observed (y) values: y = 1.lOx + 0.13 nmol/L (Spearman correlation coefficient r =0.980, n = 31). The regression curve is presented in Figure 2B .
Precision. Within-assay precision was calculated from 10 replicate measurements in one EIA. Between-assay precision was assessed from repeated analysis in 10 consecutive ELAs (Table 1) .
Serum EstradiolConcentrations
Comparison of RIA and EIA results. E2 concentrations of 284 serum samples between 0.46 and 14.7 Table 3 summarizes results of the comparison of the E2 determinations with the present EIA and with the four commercial RIA kits.
Monitoring of ovulation induction. The ovulation cycles of three patients are presented in Figure 3 .
Discussion
Enzymes used as labels in immunoassays offer some advantages over radioisotopes: they are safer to use, enzyme-labeled antigens are stable for >6 months, and no expensive measuring equipment is needed to perform an enzyme immunoassay.
Because existing RIAs for E2 are of the direct type (i.e., not requiring the timeconsuming and difficult extraction of E2), newly developed EIAs for E2 should preferentially also be of the direct type. When both the number of samples processed and the rate of throughput is important (e.g., in an IVF-ET program), a short assay time is of prime importance.
The present direct EIA for E2 allows assay of 42 samples in duplicate in only 2.5 h (including preparation of the reagents and data reduction). We note longer assay times for other methods, including other EIAs for E2 with (9) (10) (11) (12) (13) (14) or without extraction (8), a direct CIA (15), and commercially available RIA kits (unless multidetector 7-counting technology is used).
In addition, the present ELA is safe and simple. For the endpoint determination-the measurement of the bound fraction-we used the chromogen TMB, which has been shown to be nonmutagenic and noncarcinogenic (26, 27). The E2-HRP conjugate, stored in the dark at 4#{176}C, has been stable for more than 2 y. The use of microtiter plates as a solid phase in the present direct EIA facilitates several steps of the assay, including addition of the reagents, separation of bound and free fractions, and endpoint determination of the bound fraction.
The addition of displacing agents is necessary to obtain accurate results in the present direct enzyme immunoassay.
In this assay a combination of 10 ng of each danazol, cortisol, and mesterolone per well is ideal to displace E2 from its binding proteins, mainly sex hormone-binding globulin (28). Without displacing agents, E2 remains partially bound to its binding proteins and this results in an inaccurate measurement of the E2 concentration (21.3% lower than in the presence of displacing agents).
Concerning the specificity of the monoclonal antibody 2F9, we observed remarkable differences between crossreactivities obtained with RIA (22), CIA (15), and the present EIA (Table 2) . This was mainly due to methodological diversity. RIA and ELk are characterized by a single incubation with delayed addition of the labeled E2. In CIA two separate incubations are performed. The first incubation is with antibody and serum. Before the conjugate E2-isoluminol is added for the second incubation, serum is washed away. Apparently, this procedure is disadvantageous for cross-reacting substances that are less avidly bound by the antibody.
Some of the published EIAs for E2 have detection limits lower than the detection limit of the present assay, but all these assays require prior extraction of the steroid from the sample (9-14). One manuscript refers to a direct ELk for E2 in plasma (8). The detection limit of this latter assay, 0.15 pg/tube, is achieved with a 4-h incubation and with luminescent endpoint determination. Reducing the incubation time to 1 h (and lwninescent detection) increases the detection limit to 3 pg/tube (8). Use of a colorimetric endpoint determination and a 4-h incubation time results in a detection limit of 1.5 pg/tube (8). The present assay has a detection limit of 1.6 pg/well. This is equivalent to 0.24 nmol/L. The assay can thus reliably be used to determine E2 in sera from women enrolled in an IVF-ET program, but not for E2 measurement during the normal menstrual cycle, in the menopause, or in these ovulation-induction protocols that provide E2 concentrations generally <0.5 nmolJL. The results obtained with the present EIA compare well with results obtained with four commercial RIAkits (Table 3 ).
In conclusion, the direct EIA for E2 in serum is fast, simple, and reliable. The specificity, accuracy, and practical working range (0.5-14.7 nmol/L) of this ELA make it an attractive alternative to direct RIA methods for the determination of E2 in samples obtained from women enrolled in an WF-ET program.
